|
業務類別
|
-- |
|
業務概覽
|
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its globalfootprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025. |
| 公司地址
| 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426 |
| 電話號碼
| +81 362251111 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.daiichisankyo.co.jp |
| 員工數量
| 19765 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
-- |
20/06/2025 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
-- |
20/06/2025 |
|
|
| Ms. Shizuko Ueno |
Director |
20/06/2025 |
| Mr. Joseph Kenneth Keller |
Director |
20/06/2025 |
| Ms. Reiko Kinoshita |
Independent Director |
20/06/2025 |
| Mr. Sunao Manabe |
Executive Chairman of the Board |
20/06/2025 |
| Mr. Akihiro Watanabe |
Independent Director |
20/06/2025 |
| Mr. Takaaki Nishii |
Independent Director |
20/06/2025 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
20/06/2025 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
20/06/2025 |
| Mr. Yo Honma |
Independent Director |
20/06/2025 |
| Mr. Yasuhiro Komatsu |
Independent Director |
20/06/2025 |
|
|
|
|
